Loading...

Industry News

SynBioBeta brings you the latest news weekly to help you stay informed and learn about the latest developments in the synthetic biology industry. Subscribe to receive the latest news weekly to your inbox. Have news to share? Contact us to submit your story.

Subscribe

Stay Updated on the Latest News in Synthetic Biology

Subscribe to the Weekly SynBioBeta Digest
Subscribe

Latest News

May 2017

Ginkgo Bioworks and Robertet announce successful commercial-scale fermentation of flavor and fragrance cultured ingredient

Synthego First to Offer Over 100,000 Genomes in Powerful New CRISPR Software

ATUM Licenses Gene Design Software to Thermo Fisher Scientific

Synlogic and Mirna Therapeutics Agree to Merger

Argonne National Laboratory and National Renewable Energy Laboratory Receive Funding to Support the Blending of Gevo’s Isobutanol with Gasoline

Amyris On-Track To Double Revenue For Vitamin E Partnership With Nenter & Announces Exclusive Vitamin A License With Royal DSM

Johnson & Johnson Innovation Announces 40+ Resident Companies now at JLABS @ Toronto

Cellectis Patent Encompassing Broad Uses of Gene Editing Technologies Maintained by USPTO

Caribou Biosciences Announces Grant of a Key CRISPR-Cas9 Genome Editing Patent in Europe

Two new start-up plans win BrisSynBio’s first synthetic biology entrepreneurship competition

RebelBio Launches The Fourth Generation Of Startups – A Look At The First Five

FDA Extends Comment Period on Genome Editing Tech for Plants and Animals

Huvepharma to Utilize Intrexon’s Proprietary Fungal Expression Platform to Produce Key Animal Feed Enzyme

Royal DSM To Make Equity Investment In Amyris With the Purpose of Establishing a Long-Term Relationship

Evolva signs two new Distributor Agreements in Europe for Veri-teTM

Amyris Announces Much Better Than Expected Sales Of Farnesene To Meet Accelerated Demand For Liquid Farnesene Rubber By Global Tire Brands

Opentrons Launches 2x Faster OT-One S Line of Personal Pipetting Robots

SB7.0 Session 3: Art, Critical Design, Critique, Our World.

Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes

Calysta Completes $40 Million Series D Financing